Genentech
VC Fund
South San Francisco, United States
Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline.The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche andGenentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche.Genentech was founded in 1976 by
- Total investments:
- 16
- Last investment:
- Lead investor:
- 38%
Last updated:
For AI agents: llms.txt
Industries Genentech invests in
Stages Genentech invests in
Countries Genentech invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Aaron Goerke
|
|||
Bill Anderson
|
|||
Brian Armbrust
|
|||
|
Cadapakam Venkatramani
|
|||
David Choy
|
Investment Focus
Industry
- Biotechnology 9 (56%)
- Health Care 7 (44%)
- Medical 6 (38%)
- Therapeutics 4 (25%)
- Genetics 2 (13%)
Stage
- Funding Round 3 (19%)
- Series A 2 (13%)
- Series B 2 (13%)
- Post-IPO Equity 2 (13%)
- Seed 1 (6%)
Country
- United States 12 (75%)
- United Kingdom 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Aaron Goerke
South San Francisco Quality Site Head, Executive Director
|
South San Francisco Quality Site Head, Executive Director | Total investments: 0 | Find email | |
|
Bill Anderson
Sr. Group Controller
|
Sr. Group Controller | Total investments: 0 | Find email | |
|
Brian Armbrust
Senior Director, People & Culture | Global Business Partner, Pharma Product Development
|
Senior Director, People & Culture | Global Business Partner, Pharma Product Development | Total investments: 0 | Find email | |
|
Cadapakam Venkatramani
Senior Scientist
|
Senior Scientist | Total investments: 0 | Find email | |
|
David Choy
Staff Scientific Researcher
|
Staff Scientific Researcher | Total investments: 0 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Science Center
|
The University City Science Center accelerates technology commercialization, regional economic development, and the market availability of life-enhancing scientific breakthroughs by bringing together innovations, scientists, entrepreneurs, funding, laboratory facilities, and business services. Established in 1963 and headquartered inPhiladelphia, PA, the Science Center was the first, and remains the largest, urban research park in the United States. Graduate organizations and current residents of the University City Science Center’s Port business incubators have created more than 15,000 jobs that remain in the Greater Philadelphia region today and contribute more than $9 billion to the regional economy annually. | $300K / Grant / Feb 04, 2026 | |
The 15 White Coats
|
The 15 White Coats is a dynamic non-profit organization whose aim is to improve diversity in the medical sector by giving scholarships, mentorship, and support to underrepresented students pursuing medical degrees. | Seed / Aug 25, 2023 | |
Yale Cancer Center
|
Yale Cancer Center is a cancer treatment center that provides prevention, detection, diagnosis, and treatment for cancer. They provide treatments for patient care,oncology, and hematology. | Mar 06, 2023 | |
|
Yale Cancer Center
|
Yale Cancer Center is a cancer treatment center that provides prevention, detection, diagnosis, and treatment for cancer. They provide treatments for patient care,oncology, and hematology. | Mar 05, 2023 | |
Adaptimmune
|
Adaptimmune develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroys cancerous or infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses.The company was incorporated in 2007 and is based in Abingdon,United Kingdom. | $150M / Post-IPO Equity / Sep 07, 2021 | |
Rock Health Capital
|
Rock Health Capital is a full-service seed fund that invests in and supports startups working in digital health. The company invests in entrepreneurs working at the intersection of healthcare and technology. Rock Health Capital is a digital health-focused investment firm. | $4M / Jun 01, 2012 | |
Constellation Pharmaceuticals
|
Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression. | Series C / Jan 17, 2012 | |
Curis
|
Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. In expanding its drug development efforts in the field of cancer through its proprietary targeted cancer programs, Curis is building upon its previousexperiences in targeting signaling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis' website at www.curis.com. | Post-IPO Equity / Dec 23, 2011 | |
|
Curis
|
Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. In expanding its drug development efforts in the field of cancer through its proprietary targeted cancer programs, Curis is building upon its previousexperiences in targeting signaling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis' website at www.curis.com. | Post-IPO Equity / Nov 09, 2011 | |
23andMe
|
23andMe is a leading genetics-led health company dedicated to helping individuals understand the human genome. Through its consumer platform, the company provides actionable insights into ancestry, inherited traits, and genetic health risks, empowering people to take a proactive and preventative approach to their long-term wellness. By makinggenetic information accessible and understandable, 23andMe helps users discover their heritage while identifying potential health predispositions.Beyond its consumer services, the organization operates the 23andMe Research Institute, a mission-driven initiative that collaborates with the global scientific community to accelerate medical breakthroughs. With one of the world's largest databases of consented genetic and phenotypic information, the company is at the forefront of therapeutic discovery and precision medicine. 23andMe remains committed to its goal of leveraging genetic data to improve human health, drive scientific innovation, and provide researchers with the tools needed to combat complex diseases. | Series A / Oct 03, 2007 | |
| See all 16 investments → | |||
Co-Investors
HealthCare Ventures
3 deals together
Boehringer Ingelheim
2 deals together
Duke University
2 deals together
Gilead Sciences
2 deals together
NIF Ventures
2 deals together
Rho Ventures
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Genentech invest in?
Genentech invests primarily in Biotechnology, Health Care and Medical startups, most often at Funding Round and Series A stage. Most of the 16 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Genentech?
Public channels for Genentech include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Genentech?
The team at Genentech includes Aaron Goerke (South San Francisco Quality Site Head, Executive Director), Bill Anderson (Sr. Group Controller) and Brian Armbrust (Senior Director, People & Culture | Global Business Partner, Pharma Product Development), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
